FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007405429> ?p ?o ?g. }

• W2007405429 abstract "The reversible posterior leukoencephalopathy syndrome is a clinical/radiological syndrome characterized by headache, seizures, impaired vision, acute hypertension, and typical magnetic resonance imaging findings. There are several reports in the literature that depict its occurrence in cancer patients. The list of common anticancer and supportive care drugs that predispose to reversible posterior leukoencephalopathy syndrome is expanding and includes not only a large number of chemotherapeutic agents but also an increased number of new targeted drugs, particularly angiogenesis inhibitors such as bevacizumab,sorefenib and sunitinib. Pazopanib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit which after a positive phase III randomized clinical trial in patients with advanced renal cell cancer received FDA approval for the treatment of advanced renal cell carcinoma. Until now no cases of reversible posterior leukoencephalopathy syndrome induced by pazopanib have been reported.We present the case of a 40 years old female patient with heavily pre-treated metastatic renal cell carcinoma who received pazopanib as salvage treatment. After 21 days of pazopanib therapy the patient referred to the emergency department with epileptic seizure, impaired vision at both eyes and headache. MRI of the brain revealed subcortical oedema at the occipital and parietal lobes bilaterally. She was treated with anticonvulsants, i.v. administration of mannitol and antihypertensives and she recovered completely from her symptoms and was discharged on the tenth hospital day. A brain MRI performed 3 weeks after showed that the subcortical oedema had been subsided.In conclusion this is the first case of pazopanib induced reversible posterior leukoencephalopathy syndrome. Although usually reversible, this syndrome is a serious and potentially life threatening adverse effect, if untreated, that should be considered by physicians treating metastatic renal cell carcinoma patients with pazopanib." @default.
• W2007405429 created "2016-06-24" @default.
• W2007405429 creator A5002322145 @default.
• W2007405429 creator A5004616080 @default.
• W2007405429 creator A5009113561 @default.
• W2007405429 creator A5021977622 @default.
• W2007405429 creator A5025008706 @default.
• W2007405429 creator A5026781248 @default.
• W2007405429 creator A5030128192 @default.
• W2007405429 creator A5043808542 @default.
• W2007405429 creator A5055890893 @default.
• W2007405429 creator A5076032623 @default.
• W2007405429 date "2012-10-22" @default.
• W2007405429 modified "2023-09-25" @default.
• W2007405429 title "Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib" @default.
• W2007405429 cites W1980371181 @default.
• W2007405429 cites W1991690125 @default.
• W2007405429 cites W1996670817 @default.
• W2007405429 cites W2035387891 @default.
• W2007405429 cites W2040445398 @default.
• W2007405429 cites W2047250311 @default.
• W2007405429 cites W2052000133 @default.
• W2007405429 cites W2066298193 @default.
• W2007405429 cites W2067978628 @default.
• W2007405429 cites W2093089862 @default.
• W2007405429 cites W2100148558 @default.
• W2007405429 cites W2134744700 @default.
• W2007405429 cites W2138825040 @default.
• W2007405429 cites W2244517497 @default.
• W2007405429 cites W2326297993 @default.
• W2007405429 cites W2337968495 @default.
• W2007405429 cites W2615633554 @default.
• W2007405429 cites W4239884400 @default.
• W2007405429 cites W74687677 @default.
• W2007405429 doi "https://doi.org/10.1186/1471-2407-12-489" @default.
• W2007405429 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3487903" @default.
• W2007405429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23088634" @default.
• W2007405429 hasPublicationYear "2012" @default.
• W2007405429 type Work @default.
• W2007405429 sameAs 2007405429 @default.
• W2007405429 citedByCount "33" @default.
• W2007405429 countsByYear W20074054292013 @default.
• W2007405429 countsByYear W20074054292014 @default.
• W2007405429 countsByYear W20074054292015 @default.
• W2007405429 countsByYear W20074054292016 @default.
• W2007405429 countsByYear W20074054292017 @default.
• W2007405429 countsByYear W20074054292018 @default.
• W2007405429 countsByYear W20074054292019 @default.
• W2007405429 countsByYear W20074054292020 @default.
• W2007405429 countsByYear W20074054292021 @default.
• W2007405429 countsByYear W20074054292022 @default.
• W2007405429 countsByYear W20074054292023 @default.
• W2007405429 crossrefType "journal-article" @default.
• W2007405429 hasAuthorship W2007405429A5002322145 @default.
• W2007405429 hasAuthorship W2007405429A5004616080 @default.
• W2007405429 hasAuthorship W2007405429A5009113561 @default.
• W2007405429 hasAuthorship W2007405429A5021977622 @default.
• W2007405429 hasAuthorship W2007405429A5025008706 @default.
• W2007405429 hasAuthorship W2007405429A5026781248 @default.
• W2007405429 hasAuthorship W2007405429A5030128192 @default.
• W2007405429 hasAuthorship W2007405429A5043808542 @default.
• W2007405429 hasAuthorship W2007405429A5055890893 @default.
• W2007405429 hasAuthorship W2007405429A5076032623 @default.
• W2007405429 hasBestOaLocation W20074054291 @default.
• W2007405429 hasConcept C126322002 @default.
• W2007405429 hasConcept C143998085 @default.
• W2007405429 hasConcept C2776694085 @default.
• W2007405429 hasConcept C2777472916 @default.
• W2007405429 hasConcept C2777802072 @default.
• W2007405429 hasConcept C2778439243 @default.
• W2007405429 hasConcept C2778583010 @default.
• W2007405429 hasConcept C2779134260 @default.
• W2007405429 hasConcept C2779490328 @default.
• W2007405429 hasConcept C71924100 @default.
• W2007405429 hasConceptScore W2007405429C126322002 @default.
• W2007405429 hasConceptScore W2007405429C143998085 @default.
• W2007405429 hasConceptScore W2007405429C2776694085 @default.
• W2007405429 hasConceptScore W2007405429C2777472916 @default.
• W2007405429 hasConceptScore W2007405429C2777802072 @default.
• W2007405429 hasConceptScore W2007405429C2778439243 @default.
• W2007405429 hasConceptScore W2007405429C2778583010 @default.
• W2007405429 hasConceptScore W2007405429C2779134260 @default.
• W2007405429 hasConceptScore W2007405429C2779490328 @default.
• W2007405429 hasConceptScore W2007405429C71924100 @default.
• W2007405429 hasIssue "1" @default.
• W2007405429 hasLocation W20074054291 @default.
• W2007405429 hasLocation W20074054292 @default.
• W2007405429 hasLocation W20074054293 @default.
• W2007405429 hasLocation W20074054294 @default.
• W2007405429 hasOpenAccess W2007405429 @default.
• W2007405429 hasPrimaryLocation W20074054291 @default.
• W2007405429 hasRelatedWork W2070478388 @default.
• W2007405429 hasRelatedWork W2079778594 @default.
• W2007405429 hasRelatedWork W2119565846 @default.
• W2007405429 hasRelatedWork W2154171266 @default.
• W2007405429 hasRelatedWork W2254527377 @default.
• W2007405429 hasRelatedWork W2537255970 @default.
• W2007405429 hasRelatedWork W2557225468 @default.
• W2007405429 hasRelatedWork W2767323531 @default.
• W2007405429 hasRelatedWork W3023180431 @default.

• next